Lipid Nanotechnology

Mashaghi, Samaneh; Jadidi, Tayebeh; Koenderink, Gijsje H.; Mashaghi, Alireza

doi:10.3390/ijms14024242

Cited by 205 publications

(129 citation statements)

References 304 publications

(292 reference statements)

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…All classes of emulsifiers (with respect to charge and molecular weight) can be used to stabilize the lipid dispersion. It has been found that an emulsifier combination may prevent particle agglomeration more efficiently [27]. The lipid NPs combine the advantages of lipid emulsion and polymeric NPs while overcoming the temporal and in vivo stability issues that trouble the conventional and nanoscale delivery approaches [28].…”

Section: Novel Delivery Modalitiesmentioning

confidence: 99%

Introductory Chapter: Drug Delivery Concepts

Maiti¹,

Sen²

2017

Advanced Technology for Delivering Therapeutics

View full text Add to dashboard Cite

Section: Novel Delivery Modalitiesmentioning

confidence: 99%

Introductory Chapter: Drug Delivery Concepts

Maiti¹,

Sen²

2017

Advanced Technology for Delivering Therapeutics

View full text Add to dashboard Cite

“…[4,15,16] The use of lipid-based carriers is further beneficial to research on siRNA delivery because it has been demonstrated that encapsulating RNA with lipids not only decreases the degradation rates of the RNA but also increases cellular uptake of the nucleic acid material. [19] However, even though there have been many advances in developing lipid-based carriers for delivery, their introduction and application into clinical practice has been slow partly due to problems in pharmaceutical manufacturing as well as regulations set out by the government. [23] …”

Section: Lipid-based Vectorsmentioning

confidence: 99%

An Overview of Various Carriers for siRNA Delivery

Marquez¹,

Madu²,

Lü³

2018

Oncomedicine

View full text Add to dashboard Cite

RNA interference through the use of short interfering molecules known as short interfering RNA (siRNA) has the potential to greatly advance research in treatments for many diseases because it has the ability to silence the expression of specific genes by helping degrade target mRNA. However, challenges to siRNA delivery have made the development of safe and effective delivery systems paramount in siRNA research. Various types of delivery systems have been proposed and investigated for siRNA delivery and therapy. Although viral vectors have been established to be the most effective in delivering siRNA molecules, they also raise many concerns over biosafety, especially concerning immunogenicity. Therefore, many researchers have begun to investigate and study non-viral vectors. Non-viral vectors are studied because they are typically considered to be safer than viral vectors albeit less efficient as well. The three general non-viral vectors that have been studied for siRNA delivery are lipid-based, non-lipid organic-based, and non-lipid inorganic-based carriers. Within those general parameters of non-viral vector classification are subtypes that are each unique with their own characteristic benefits and downsides. Many of these carriers, as well as even naked siRNA, do have the potential to be modified so that siRNA delivery could be further enhanced with benefits such as greater stability and duration. Researchers still must be wary with alterations as to not interfere with siRNA function. Currently, widespread siRNA therapeutics are still out of reach, but as more advancements in siRNA research including research on their delivery mechanisms are established, the goal of integrating siRNA therapy into the treatment of a multitude of diseases becomes increasingly more of a possibility. Researchers are currently investigating how siRNA can be used to not just treat cancer but ocular and neurodegenerative diseases as well as many others. There are still many obstacles to face and overcome before siRNA therapy can be implemented into the treatment of many diseases, and more research must still be conducted concerning siRNA delivery systems. Many advancements pertaining to siRNA carriers have been made, and many more are likely on their way.

show abstract

“…These networks can be designed to perform useful tasks. Lipids and surfactants are typically used to prevent the merging of the contacting droplets [75]. Despite being thin, bilayers form robust interfaces, allowing for flexible network architectures.…”

Section: Droplet-based Micro and Nanotechnologymentioning

confidence: 99%

Droplet microfluidics: A tool for biology, chemistry and nanotechnology

Mashaghi

Abbaspourrad

Weitz

et al. 2016

TrAC Trends in Analytical Chemistry

Self Cite

322

188

View full text Add to dashboard Cite

The ability to perform laboratory operations on small scales using miniaturized devices provides numerous benefits, including reduced quantities of reagents and waste as well as increased portability and controllability of assays. These operations can involve reaction components in the solution phase and as a result, their miniaturization can be accomplished through microfluidic approaches. One such approach, droplet microfluidics, provides a high-throughput platform for a wide range of assays and approaches in chemistry, biology and nanotechnology. We highlight recent advances in the application of droplet microfluidics in chipbased technologies, such as single-cell analysis tools, small-scale cell cultures, in-droplet chemical synthesis, high-throughput drug screening, and nanodevice fabrication.

show abstract

Lipid Nanotechnology

Cited by 205 publications

References 304 publications

Introductory Chapter: Drug Delivery Concepts

Introductory Chapter: Drug Delivery Concepts

An Overview of Various Carriers for siRNA Delivery

Droplet microfluidics: A tool for biology, chemistry and nanotechnology

Contact Info

Product

Resources

About